Lubiprostone + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Opioid-Induced Bowel Dysfunction

Conditions

Opioid-Induced Bowel Dysfunction

Trial Timeline

Aug 1, 2007 → Mar 1, 2009

NCT ID

NCT00595946

About Lubiprostone + Placebo

Lubiprostone + Placebo is a phase 3 stage product being developed by Mallinckrodt Pharmaceuticals for Opioid-Induced Bowel Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00595946. Target conditions include Opioid-Induced Bowel Dysfunction.

What happened to similar drugs?

4 of 20 similar drugs in Opioid-Induced Bowel Dysfunction were approved

Approved (4) Terminated (8) Active (9)

✅Naldemedine + PlaceboShionogiApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03097861	Phase 3	Completed	Mar 13, 2017	Aug 17, 2017	Chronic Idiopathic Constipation
NCT01298219	Phase 3	Completed	Dec 1, 2010	Nov 1, 2011	Opioid-induced Bowel Dysfunction
NCT00595946	Phase 3	Completed	Aug 1, 2007	Mar 1, 2009	Opioid-Induced Bowel Dysfunction
NCT00597428	Phase 3	Completed	Aug 1, 2007	Mar 1, 2009	Opioid-Induced Bowel Dysfunction
NCT00399542	Phase 3	Completed	May 1, 2005	Jul 1, 2006	Irritable Bowel Syndrome

Competing Products

20 competing products in Opioid-Induced Bowel Dysfunction

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35